AKARI THERAPEUTICS PLC-ADR

AKTX represents the common stock of Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company. Its shares trade on the Nasdaq Capital Market under the ticker AKTX. The stock gives investors an ownership interest in the company and its pipeline of investigational therapies. Because AKTX is a small-cap, clinical-stage company, its share price can be sensitive to research and development updates and financing activities.

Recent performance for AKTX depends on the latest trading session and cannot be stated from static information. The stock detail page shows current and historical price data, including daily moves and longer-term trends. For the most accurate recent performance, review the price chart and performance figures displayed on this page. Those figures reflect actual market activity rather than estimates.

The latest AKTX price is available on this stock detail page, along with the current quote, day range, and trading volume. Because prices change throughout the trading day, the page updates to reflect the most recent market data. Checking the live quote here is the most direct way to see where AKTX is trading right now.

Valuation for a clinical-stage biopharmaceutical company like AKTX often relies on more than standard earnings multiples because the company may not yet be consistently profitable. Investors commonly review cash position, pipeline progress, collaboration terms, and potential market size for its product candidates. Traditional metrics such as price-to-book or enterprise value can also be considered. The valuation metrics displayed on this page provide AKTX-specific figures for further analysis.

AKTX faces risks common to clinical-stage biopharmaceutical companies, including clinical trial failures, regulatory delays, reliance on external financing, and competition from larger drugmakers. Share dilution may occur if the company raises additional capital. Because revenue may be limited or absent, the stock can be volatile and sensitive to pipeline news. These factors can materially affect AKTX's business and share price.

Earnings releases, quarterly reports, and annual filings for AKTX are typically available through the company's investor relations website and the SEC's EDGAR database. This stock detail page may also list earnings dates and reported results. Reviewing those filings helps investors understand revenue, expenses, cash burn, and progress in AKTX's development programs.